Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
BioNTech SE
ISIN US09075V1026
|WKN A2PSR2
Market cap (in EUR)
25,101 m
Country
Germany
Sector
Healthcare
Dividend yield
0.00%
Overview
Quote
Advertisement
Own The World. Get instant, global diversification with Invesco ETFs. Capital at risk. Find out more In paid partnership.
Description
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals Germany
Chart
Financials
Key metrics
| Market capitalisation, EUR | 25,101 m |
| EPS, EUR | -6.73 |
| P/B ratio | 1.4 |
| P/E ratio | 159.5 |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 2,871 m |
| Net income, EUR | -1,137 m |
| Profit margin | -39.59% |
What ETF is BioNTech SE in?
There are 40 ETFs which contain BioNTech SE. All of these ETFs are listed in the table below. The ETF with the largest weighting of BioNTech SE is the VanEck Genomics and Healthcare Innovators UCITS ETF A.
Performance
Returns overview
| YTD | +4.29% |
| 1 month | -3.79% |
| 3 months | +2.12% |
| 6 months | +7.00% |
| 1 year | -5.61% |
| 3 years | -18.08% |
| 5 years | -59.78% |
| Since inception (MAX) | +557.70% |
| 2025 | -21.19% |
| 2024 | +8.67% |
| 2023 | -35.01% |
| 2022 | -29.26% |
Monthly returns in a heat map
Risk
Risk metrics in this section:
- Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
- Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
- Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
Risk overview
| Volatility 1 year | 43.00% |
| Volatility 3 years | 43.65% |
| Volatility 5 years | 49.72% |
| Return per risk 1 year | -0.13 |
| Return per risk 3 years | -0.15 |
| Return per risk 5 years | -0.33 |
| Maximum drawdown 1 year | -29.12% |
| Maximum drawdown 3 years | -38.44% |
| Maximum drawdown 5 years | -77.43% |
| Maximum drawdown since inception | -80.90% |
Rolling 1 year volatility
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
